Why is it in the news?
IIT Bombay study demonstrated a gentler method for recovering lab-grown T-cells.
May improve affordability and reliability of CAR T-cell therapy in India.
Category: Science and Technology
Important Points:
● T-cells are white blood cells that detect and destroy abnormal cells
● CAR T-cell therapy involves genetic engineering of T-cells
● Uses Chimeric Antigen Receptors (CARs) to target cancer cells
● Approved for leukemia and lymphoma
● NexCAR19 approved in 2023 as India’s first indigenous CAR-T therapy
● Traditional extraction used Trypsin, damaging cell membranes
● Study used Accutase for gentler detachment from 3D scaffolds
● Accutase-recovered cells showed higher survival and preserved immune function
● Global CAR-T therapy cost Rs 3–4 crore
● Innovation reduces cell waste and improves treatment consistency